AtCor signs $800K contract expansion
AtCor Medical (ASX:ACG) has expanded an existing contract to supply its SphygmoCor diagnostic to the tune of $800,000.
Following its recent announcement of a 1H13 profit, AtCor Medical has now added a further $800,000 to its expected revenues following the signing of a contract expansion to an existing customer.
AtCor will supply SphygmoCor to a major pharmaceutical company to support clinical trials in North and South America, Europe and Asia.
SphygmoCor is the company’s device for measuring central aortic blood pressures and arterial stiffness non-invasively.
“We are delighted to have secured this expansion contract,” said AtCor Medical CEO Duncan Ross.
“The non-invasive measurement of central blood pressure and arterial stiffness is particularly important for drug development, which requires accurate, insightful data to fully understand the efficacy of new drugs.”
AtCor (ASX:ACG) was up 1% at 10c in light trading as of around 11 am Monday morning.
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
Prenatal stress leaves a molecular mark on newborns
An international study has uncovered how stress experienced during pregnancy can affect newborns...
More effective antibiotic found for Lyme disease
Researchers have found that piperacillin, an antibiotic in the same class as penicillin,...
